Use of novel oral anticoagulants in patients with atrial fibrillation and moderate to severe renal dysfunction: findings from a prospective national registry

25 August 2018 (00:00 - 00:00)

Organised by:

Sign in to view the resources

About the speaker

Associate Professor Alon Barsheshet

Rabin Medical Centre, Petah Tikva (Israel)

9 More presentations in this session

Presentation thumbnail

Comparison of ischemic stroke risk in atrial fibrillation patients with or without myocardial infarction: A propensity score matched study

Doctor G. Yoon (Incheon, KR)

Presentation thumbnail

Effectiveness and safety of rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and heart failure

Professor C. Coleman (Storrs, US)

Abstract Slides

Presentation thumbnail

Prognostic impact of inappropriate doses of direct oral anticoagulants in clinical practice: a subanalysis of the FANTASIIA registry, a prospective, nationwide, real-world, observational study.

Doctor M. Ruiz Ortiz (Cordoba, ES)

Abstract Slides

Presentation thumbnail

Incidence of incomplete surgical left atrial appendage closure

Assistant Professor Y. Kim (GangNeung, KR)

Abstract Slides

Presentation thumbnail

Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes in the daily practice

Doctor T. Chao (Taipei, TW)

Access the full session

Session thumbnail

Poster Session 5 - Atrial fibrillation - Stroke prevention 3

The Event

ESC Congress 2018

25 August - 29 August 2018

You may be interested in

Congress Presentation

State-of-the-art lecture on stroke prevention in atrial fibrillation

Congress Presentation

Device-detected or clinically diagnosed atrial fibrillation: the same decision for oral anticoagulation therapy - pro

Congress Session

Stroke prevention in clinical and subclinical atrial fibrillation

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources